

Atezolizumab

Section	Indications
<p>Immunomodulators</p> <p>Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion</p>	<p>Other specified malignant neoplasms of bronchus or lung</p> <p>Therapeutic equivalent to pembrolizumab for</p> <p>Other specified malignant neoplasms of bronchus or lung</p>

Cemiplimab

Section	Indications
<p>Immunomodulators</p>	<p>Therapeutic equivalent to pembrolizumab for</p> <p>Other specified malignant neoplasms of bronchus or lung</p>

Daratumumab

Section	Indications
<p>Immunomodulators</p> <p>Parenteral > General injections > IV: 100 mg per 5 mL; 400 mg per 20 mL</p>	<p>Plasma cell myeloma</p>

Durvalumab

Section	Indications
<p>Immunomodulators</p> <p>Parenteral > General injections > IV: 120 mg per 2.4 mL in vial; 500 mg per 10 mL in vial</p>	<p>Other specified malignant neoplasms of bronchus or lung</p>

Filgrastim

Section	Indications
<p>Immunomodulators</p> <p>Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial</p>	<p>Acquired neutropaenia</p>

Lenalidomide

Section	Indications
<p>Immunomodulators</p> <p>Oral > Solid: 25 mg</p>	<p>Plasma cell myeloma</p>

Nivolumab

Section

Immunomodulators

Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion

Indications

Other specified malignant neoplasms of bronchus or lung

Melanoma of skin

Pegfilgrastim

Section

Immunomodulators

Parenteral > General injections > SC: 6 mg per 0.6 mL in pre-filled syringe

Indications

Acquired neutropaenia

Pembrolizumab

Section

Immunomodulators

Parenteral > General injections > IV: 50 mg powder for injection

Indications

Therapeutic equivalent to nivolumab for

Melanoma of skin

Other specified malignant neoplasms of bronchus or lung

Thalidomide

Section

Immunomodulators

Oral > Solid: 50 mg

Indications

Plasma cell myeloma

Tislelizumab

Section

Immunomodulators

Parenteral > General injections > IV: 100 mg per 10 mL

Indications

Malignant neoplasms of urinary tract

Hodgkin lymphoma

Other specified malignant neoplasms of bronchus or lung

Toripalimab

Section

Immunomodulators

Parenteral > General injections > IV: 240 mg per 6 mL in vial

Indications

Malignant neoplasms of nasopharynx

Malignant neoplasms of oesophagus